TY - JOUR
T1 - Standard therapy for patients with myelodysplastic syndromes
AU - Al-Ameri, Ali
AU - Cherry, Mohamad
AU - Garcia-Manero, Guillermo
AU - Quintás-Cardama, Alfonso
PY - 2011/8
Y1 - 2011/8
N2 - The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.
AB - The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.
KW - Azacitidine
KW - Decitabine
KW - Lenalidomide
KW - MDS
KW - Myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=84555209314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84555209314&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2011.06.008
DO - 10.1016/j.clml.2011.06.008
M3 - Review article
C2 - 21816368
AN - SCOPUS:84555209314
SN - 2152-2650
VL - 11
SP - 303
EP - 313
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 4
ER -